Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.

ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues

WARSAW, Ind. , Nov. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Jefferies London Healthcare Conference on November 19, 2024, with a fireside chat at 11:00 a.m.

Zimmer Biomet to Present at Jefferies London Healthcare Conference

On Wednesday, Zimmer Biomet Holdings, Inc ZBH reported third-quarter adjusted EPS of $1.74, up from $1.65 a year ago, in line with the Street estimates.

Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts

Zimmer Biomet delivers strong performance across segments and regions in the third quarter of 2024.

ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants David DeMartino – Senior Vice President-Investor Relations Ivan Tornos – President and Chief Executive Officer Suketu Upadhyay – Chief Financial Officer and Executive Vice President-Finance, Operations and Supply Chain Conference Call Participants Travis Steed – Bank of America Vik Chopra – Wells Fargo David Roman – Goldman Sachs Allen Gong – JPMorgan Matthew O'Brien – Piper Sandler Chris Pasquale – Nephron Steve Lichtman – Oppenheimer Sophia Knopp – Evercore ISI Richard Newitter – Truist Securities Jeff Johnson – Baird Caitlin Cronin – Canaccord Mike Matson – Needham & Company Shagun Singh – RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, October 30, 2024.

Zimmer Biomet Holdings, Inc. (ZBH) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zimmer (ZBH) Reports Q3 Earnings: What Key Metrics Have to Say

Hip implant maker Zimmer Biomet lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations.

Implant maker Zimmer Biomet lowers full-year profit forecast

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago.

Zimmer Biomet (ZBH) Misses Q3 Earnings Estimates

Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency1 basis Third quarter diluted earnings per share were $1.23; adjusted1 diluted earnings per share were $1.74 Company updates 2024 financial guidance, reducing and narrowing range for full year outlook WARSAW, Ind. , Oct. 30, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2024.

Zimmer Biomet Announces Third Quarter 2024 Financial Results

Bio-Rad Laboratories

Bio-Techne

Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.

What to Expect From These 3 MedTech Stocks This Earnings Season

Evaluate the expected performance of Zimmer (ZBH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Countdown to Zimmer (ZBH) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Company's Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies Including OrthoGrid Hip AI® and HAMMR™ Automated Hip Impaction System WARSAW, Ind. , Oct. 28, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced plans for the broad commercial launch of the Z1™ Femoral Hip System (Z1 System) for total hip arthroplasty at the 2024 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).

Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth

Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

WARSAW, Ind. , Oct. 9, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, October 30, 2024 at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2024 Financial Results

Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Large Joint Devices Market Size, Share, and Trends Analysis Global 2024-2030 MedSuite Includes: Knee Replacement Market, Hip Replacement Market, and 1 more" report has been added to ResearchAndMarkets.com's offering.

Large Joint Devices Market Size, Share, and Global Trends Analysis 2024-2030: Zimmer Biomet Leads Global Hip Reconstruction Market with Taperloc and Arcos Systems

Zimmer Biomet, a leader in musculoskeletal health, excels in knee and hip replacements, and surgical robots, making it a sticky choice for many orthopedic surgeons. Competitive advantages include strong surgeon loyalty, technological innovation with the ROSA® Robot, and a global consignment-based distribution model ensuring product availability. Challenges include regulatory hurdles, reliance on elective surgeries, supply chain risks, and fierce competition from companies like Stryker.

Zimmer Biomet: The Undervalued Titan Of Joint Replacements

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?

Shares of Zimmer Biomet Holdings (ZBH) dropped nearly 9% after the manufacturer of artificial joint replacements and other orthopedic products warned the implementation of a new enterprise resources planning (ERP) system would hit sales and profits in 2024.

Zimmer Biomet Stock Falls After the Medtech Firm Warns of Software Switch Impact

Zimmer Biomet stock tumbled Thursday after the medtech company said implementing a new enterprise system would slug 2024 sales by 1%.

Zimmer Biomet Hammered, Sales Expected To Take A Surprise 1% Hit

WARSAW, Ind. , Sept. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that David DeMartino will join the Company as Senior Vice President, Investor Relations, effective September 9, 2024.

Zimmer Biomet Names David DeMartino as Senior Vice President, Investor Relations

Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.

Should You Consider Retaining ZBH Stock in Your Portfolio Now?

In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.

Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure

WARSAW, Ind. , Aug. 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2024.

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024

WARSAW, Ind. , Aug. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will present at two upcoming healthcare conferences in September.

News for Zimmer Biomet Hlds Stock (ZBH)